i2c Pharmaceutical Services holds a patent for a unique formulation approach for HFA pMDI. Extensive in-vitro characterisation of formulations manufactured using this technique have been undertaken.
In summary, the use of the novel formulation approach for HFA suspension systems permits:
-
Low energy dispersion of micronised drug particles.
-
Robust pMDI formulations.
-
Good aerosol performance.
-
Applicable to a variety of drugs: Salbutamol Sulphate, Fluticasone Propionate, Formoterol Fumarate, Budesonide, Budesonide/Formoterol combination and Salmeterol Xinafoate/Fluticasone Propionate combination.
-
Improved manufacturing processes.
-
Non-pulmonary depositing excipients.
i2c pharmaceutical services is actively seeking partners to participate in further development of this robust, versatile, technology. Contact us for further information. |
 |
